Also, TMB, MSI, MMRs, and DNA methylation might contribute to KIF18B dysregulation in cancers, and KIF18B is closely linked to tumor immunity and may be a potential therapeutic target for immunotherapy. The gene discussed is KIF18B; the disease is cancer.